Methofill (Methotrexate)

Methotrexate is a folate antagonist that competitively inhibits dihydrofolate reductase, an enzyme essential for converting folic acid to its active form. This inhibition blocks the synthesis of purine nucleotides and thymidylate, which are required for DNA, RNA, and protein production, thereby reducing the proliferation of malignant cells and dampening immune activation.

The dose of Methofill is individualized by the prescribing clinician based on the specific indication, patient weight or body surface area, renal and hepatic function, and treatment response. Because dosing varies widely across oncology and rheumatology protocols, only a qualified healthcare professional should determine the appropriate regimen.

Methofill is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy due to a high risk of fetal harm, including teratogenic effects. It is also not recommended during breastfeeding because methotrexate can be excreted in breast milk and may cause adverse effects in the infant.

To request Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Methofill (methotrexate) belongs to the antimetabolite class, whereas alternatives such as biologic disease‑modifying antirheumatic drugs (e.g., adalimumab) target specific cytokines. Methotrexate is generally less expensive and administered by injection, but it may have broader systemic toxicity. Choice of therapy depends on disease severity, patient comorbidities, and response to prior treatments.

Methofill should be stored in a refrigerated environment between 2 °C and 8 °C. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. If a temporary temperature excursion occurs, consult the product’s stability data before use.

Methofill is supplied as a sterile solution for injection and may be given intravenously or subcutaneously by a qualified healthcare professional. The route, infusion rate, and frequency are determined by the treating physician according to the specific indication and patient tolerance.

The most critical adverse events include bone marrow suppression (which can lead to severe anemia, neutropenia, or thrombocytopenia), hepatotoxicity (potentially progressing to liver failure), and pulmonary toxicity (manifesting as cough, dyspnea, or interstitial pneumonitis). Prompt monitoring of blood counts, liver function, and respiratory status is essential.

Methofill is contraindicated in pregnant or breastfeeding women, patients with severe hepatic impairment, significant renal dysfunction, known hypersensitivity to methotrexate or its excipients, and individuals receiving live vaccines. Clinicians should also exercise caution in patients with pre‑existing bone marrow disorders or uncontrolled infections.